For Immediate Release Chicago, IL – October 01, 2015 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includethe Regeneron (REGN), Vertex (VRTX), Gilead (GILD), Biogen (BIIB) and Celgene ( CELG). Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Wednesday’s Analyst Blog: Biotech Stock Roundup Once again, pricing concerns overshadowed all other developments in the biotech sector over the last five trading days. The NASDAQ Biotechnology Index was down a sharp 13.5% with investors remaining jittery about possible legislative action regarding escalating prices of drugs (See the last biotech stock roundup here: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals ). Recap of the Week’s Most Important Stories 1. The biotech sector, which saw a major selloff ever since Democratic presidential candidate Hillary Clinton tweeted about the increasing cost of drugs, remains under pressure as concerns regarding price control refuse to abate. The situation worsened when earlier this week, House Democrats submitted an application seeking a subpoena requiring Valeant Pharmaceuticals to provide documents relating to massive price increases for a couple of drugs (Nitropress' 212% hike and Isuprel's 525% hike) acquired by the company. Concerns remain that biotech companies with high priced drugs may face similar action. 2. Regeneron (REGN) and partner Sanofi scored another win with their PCSK9 inhibitor, Praluent, gaining EU approval. Praluent, already available in the U.S., is one of the most highly-awaited new treatments to gain approval this year. (Read more: Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU ). 3. It’s been a busy week across the pond with quite a few companies gaining positive opinions from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for their experimental treatments that are currently under EU review. So, while Vertex ( VRTX) got positive opinions for its cystic fibrosis drugs - Orkambi and Kalydeco (label expansion), the CHMP is also in favor of approving Gilead’s ( GILD) once-daily single tablet regimen, Genvoya. Other products that got a positive opinion from the CHMP include Biogen’s (BIIB ) hemophilia A treatment, Elocta and Celgene’s (CELG) blood cancer treatment, Vidaza (label expansion) among others. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
|